<DOC>
	<DOCNO>NCT02955732</DOCNO>
	<brief_summary>We aim characterize bioavailability pharmacokinetics dexmedetomidine intranasal dose employ pharmacometric method otherwise healthy 1 month 11 year age child schedule minor surgery procedure require sedation anesthesia .</brief_summary>
	<brief_title>Pharmacological Characteristics Intranasally Given Dexmedetomidine Paediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . The child schedule intraarticular drug injection , hernia repair , bronchoscopy another similar minor procedure magnetic resonance image require sedation anesthesia 2 . Guardians patient ( relevant ) fluent skill Finnish Swedish language ( understand give information , able give inform consent communicate study personnel ) . 3 . Age 1 month 12 year . 4 . Normal developmental status include growth ( SD 1.51.5 ) 5 . Written inform consent guardian patient ( relevant ) . 1 . A previous history intolerance study drug relate compound additive 2 . Prior drug therapy dexmedetomidine 14 day prior study . 3 . Use drug know cause enzyme induction inhibition period 30 day prior study , use natural product ( include grapefruit product ) least 14 day prior study caffeine containing product least 24 hour prior study . The use regular dos paracetamol allow . 4 . Existing recent significant disease could influence study outcome cause health hazard subject he/she would participate study . 5 . Participation clinical study involve investigational market drug product concomitantly within one month prior entry study . 6 . Clinically significant abnormal finding physical examination laboratory screen [ routine haematology ( haemoglobin , haematocrit , red blood cell count , white blood cell count , platelet ) , renal function test ( creatinine , urea ) liver function test ( bilirubin ) ] .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>